Miami Breast Cancer Conference

Kevin Kalinsky, MD, MS, discussed selective estrogen receptor downregulators being explored for the treatment of breast cancer clinical trials.

Tailored treatment available to patients with HER2-positive metastatic breast cancer based on the presence of active central nervous system disease.

In the phase 3 monarchE clinical trial, long-term follow-up results show that the benefit of abemaciclib plus endocrine therapy continued beyond 2 years.

A team-oriented approach based on guideline-directed therapies should be used by clinicians to address patients experiencing cardiotoxicity as a result of their breast cancer, according Jean-Bernard Durand, MD.

Results from 3 clinical trials show that adjuvant CDK4/6 inhibition is a good option for early-stage hormone-receptor-positive breast cancer.

Progress in the treatment of early-stage triple-negative breast cancer includes the now common use of neoadjuvant combinations of immunotherapy with chemotherapy.

Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.

According to real-world research, eribulin may be an effective treatment for patients with metastatic breast cancer who were previously treated with atezolizumab or sacituzumab govitecan.

Sara A. Hurvitz, MD, discusses the pros and cons of anthracycline treatment.

Mohammad Jahanzeb, MD, discusses the designs of landmark trials in early HER2-positive targeted therapy and the adverse events associated with those treatments.

Mark D. Pegram, MD, discusses proposed mechanisms of resistance to HER2-targeted therapies.

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the ongoing MONARCH and neoMONARCH studies in breast cancer.

According to a retrospective 4.5-year study of patients who had commercial and Medicare supplemental coverage, healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer.

Elizabeth A. Mittendorf, MD, PhD, discusses the immunotherapy combinations currently being investigated in the treatment of breast cancer.

Kimberly Blackwell, MD,&nbsp;discusses the results of the recent phase III OLYMPIAD trial, which showed olaparib (Lynparza) improved progression-free survival (PFS) versus standard chemotherapy in patients with <em>BRCA</em>-positive breast cancer.

Kelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses targeting the androgen receptor in breast cancer.

The addition of CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor (HR)&ndash;positive, HER2-negative advanced breast cancer.

Larry Norton, MD, says the so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.

Pat Whitworth, MD, discusses how surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer.

Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab as well as zoledronic acid as in patients with breast cancer.

The addition of the CDK4/6 inhibitor ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Combining eribulin with pembrolizumab for patients with metastatic triple-negative breast cancer demonstrated promising objective response rates, including a complete response, according to findings from a phase Ib/II study presented at the 2017 Miami Breast Cancer Conference.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the link between circulating tumor cells and survival outcomes in metastatic breast cancer.

The FDA’s recent approval of the first PARP inhibitor, coupled with current research, suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making, according to Hope S. Rugo, MD.

Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming severe.